INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified) (Use several sheets if necessary)

ATTY. DOCKET NO. BEAR-004

SERIAL NO.

09/642,609

APPLICANT

Kumagai et al.

FILING DATE August 17, 2000 GROUP

1614 1653

NOW 2 8 2000 CO

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date .	Name	Class	Subclass	Filing Date If Appropriate
m	ĀĀ	5,665,700	09/09/1997	Cho et al.	514	2	RECEIVED
AVI	AB	5,981,475	11/09/1999	Reynolds	514	6	DEC - / 2000
AM	AC	6,028,053	02/22/2000	Van der Geer et al.	514	7	DEC () 4 200U

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

		Document Number	Date	Country	Class	Subclass	Trans	lation
							V25	
mil	AD	WO 99/22743.	05/14/1999	PCT			Yes	No
AU		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	00/2//	,),			
			OTHER ART (Inch	uding Author, Title, Date, Pertinent Pag	es, Etc.)			

AU	AE	Anderson et al. (1972), "Characterization of Three Sequential Polydipeptides containing Glycine." J. Mol. Biol., Vol. 67:459-468.
1	AF	Andress et al. (1987), "Osteomalacia and Aplastic Bone Disease in Aluminum-Related Osteodystrophy." Journal of Clinical Endocrinology and Metabolism, Vol. 65(1):11-16.
	AG	Andress et al. (1989), "Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal Failure." <i>The New England Journal of Medicine</i> , Vol. 321(5): 274-279.
	АН	Delmez et al. (1992), "Hyperphosphatemia: Its Consequences and Treatment in Patients with Chronic Renal Disease." <i>American Journal of Kidney Diseases</i> , Vol. 19 (4): 303-317
	AI	DeTar et al. (1967), "Sequence Peptide Polymers. III. Poly Asp(OH)-Ser(H)-Gly and Other Serine-Containing Polymers." <i>Journal of the American Chemical Society</i> , Vol. 89(12):3039-3045.
·	AJ	Emmett et al. (1991), "Calcium Acetate Control of Serum Phosphorus in Hemdialysis Patients." American Journal of Kidney Diseases, Vol. 17(5):544-550
	AK	Faugere et al. (1986), "Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis." <i>The Journal of Laboratory and Clinical Medicine</i> , Vol. 107(6):481-487.
	AL	Felsenfeld et al. (1999), "Phosphorus, Regulation of Plasma Calcium, and Secondary Hyperparathyroidism: A Hypothesis to Integrate a Historical and Modern Perspective." <i>J. Am. Soc. Nephrol.</i> , Vol. 10:878-890.
	АМ	Reichel et al. (1989), "The Role of the Vitamin D Endocrine System in Health and Disease." The New England Journal of Medicine, Vol. 320(15):980-991
	AN	Slatopolsky et al. (1973), "The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease." <i>Kidney International</i> , Vol. 4:141-145.
AM	AO	Slatopolsky et al. (1986), "Alternative Phosphate Binders in Dialysis Patients: Calcium Carbonate." Seminars in Nephrology, Vol. 6(4) supp 1: 35-41.

EXAMINER	AL	del	A.	$-\mathcal{W}$	ohamed.	DAT

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 2

INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified) (Use several sheets if necessary) ATTY. DOCKET NO. **BEAR-004** SERIAL NO.

09/642,609

APPLICANT

Kumagai et al.

FILING DATE

GROUP August 17, 2000

Ward et al. (1978), "Osteomalacic Dialysis Osteodystrophy: Evidence for a Water-borne Aetiological agent, probably aluminum." The Lancet, Vol. 1(8069): 841-845.

F:\forms\word 2k forms\form PTO-1449.doc



RECEIVED

DEC 0 4 2000

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Linder th	PATE	FEB 1 9 2002	1995	no nerso	uns are red			rademar	ed for use through 10/3 k Office: U.S. DEPAR' unless it contains a va	TMENT OF COMME	-003 ERC
Substitute for		RADEMAN					*		e if Known	TEO T	-
_						Applicati n Nun	nber	09/	642,609	A OF ES	
_		MATION DISC				Filing Date		1	ust 17, 2000		
•	STATE	EMENT BY AF	PLIC	ANT		First Named Inv	entor	KUN	AGALET AL.	3	ر ح
	(1100	a many abaata aa				Group Art Unit		4017		```	_
	(USB (as many sheets as i	ecessa	(V)		Examiner Name		TOE	Be Assigned	亥	JUUS
Sheet		1	of	<<t< b=""></t<>	EXT>>	Attorney Docket I	Number	BEA	R004	5	7
										· ig	
					U.S. F	PATENT DOCUM	MENTS			- 6	_
Examiner	Cite	U.S. Patent Documents			Name of Patentee or Applicant		Date of Publication		Pages, co	dumns, lines, Sub	coi
Initials'	No.1	Number i (if kr	ind Cod	е ² '`	of Cited Documents of Cited Documents MM-DD-YYY		ument	Passages	Relevant s or Relevant s Appear		
m		5,837,674			Kuma	agai et al.	11/17/	98	C116	7	
an		5,527,881				let et al.	06/18/	96	27	200	
1									350	130/	_
<u> </u>	_										_
				F	OREIG	N PATENT DOC	UMENTS				
		Foreign Patent	Dogge Land	nate	1		1		Boson Co	lumns, Lines,	

					FC	REIGN PATENT DOCUME	NTS		
Examiner Initials'	Cite No. ¹	Fore	eign Patent D	ocume	ents	Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
		Office ³	Number ⁴		Code ⁵ nown)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
				`					
									ļ
									-
							1		.1

		· •									
	OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS										
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Examiner

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.